James E Flynn Insider Trading $ACRS Aclaris Therapeutics, Inc.
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
James E Flynn in Aclaris Therapeutics, Inc.
Trading Symbol: ACRSIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of James E Flynn: 10% Owner
Holdings: 964,101 shares
Current Value: $24,343,550
Latest Transaction: Jul 01 2019
$ACRS Market Capitalization: $537.94M
$ACRS Previous Close: $25.25
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of James E Flynn in Aclaris Therapeutics, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jul 01 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 2.69 | 590,801 | 1,589,668 | 3,159,165 | 3.7 M to 3.2 M (-15.75 %) |
Jul 01 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 2.69 | 108,674 | 292,409 | 964,101 | 1.1 M to 964.1 K (-10.13 %) |
Jun 26 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.50 | 1,352 | 6,086 | 3,749,966 | 3.8 M to 3.7 M (-0.04 %) |
Jun 26 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.50 | 352 | 1,585 | 1,072,775 | 1.1 M to 1.1 M (-0.03 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.51 | 40,850 | 184,189 | 3,751,318 | 3.8 M to 3.8 M (-1.08 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.51 | 10,634 | 47,948 | 1,073,127 | 1.1 M to 1.1 M (-0.98 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.52 | 50,177 | 226,925 | 3,792,168 | 3.8 M to 3.8 M (-1.31 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.52 | 13,063 | 59,077 | 1,083,761 | 1.1 M to 1.1 M (-1.19 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.62 | 269,402 | 1,243,398 | 3,842,345 | 4.1 M to 3.8 M (-6.55 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.62 | 70,135 | 323,701 | 1,096,824 | 1.2 M to 1.1 M (-6.01 %) |
May 13 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 6.05 | 71,869 | 434,750 | 1,166,959 | 1.2 M to 1.2 M (-5.80 %) |
May 13 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 6.05 | 108,696 | 657,524 | 4,111,747 | 4.2 M to 4.1 M (-2.58 %) |
May 13 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 6.16 | 172,800 | 1,064,016 | 1,238,828 | 1.4 M to 1.2 M (-12.24 %) |
May 13 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 6.16 | 261,345 | 1,609,232 | 4,220,443 | 4.5 M to 4.2 M (-5.83 %) |
Jan 18 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 6.93 | 1 | 7 | 1 | |
Jan 18 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 6.97 | 1 | 7 | 1 | |
Jan 18 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 7.00 | 1 | 7 | 1 | |
Jan 02 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 7.00 | 1 | 7 | 1 | |
Dec 27 2018 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 6.89 | 1 | 7 | 1 | |
Dec 27 2018 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 6.86 | 1 | 7 | 1 | |
Dec 27 2018 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 6.92 | 1 | 7 | 1 | |
Dec 27 2018 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 6.89 | 1 | 7 | 1 | |
Dec 27 2018 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 6.86 | 1 | 7 | 1 | |
Dec 27 2018 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 6.92 | 1 | 7 | 1 | |
Dec 21 2018 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 6.95 | 1 | 7 | 1 | |
Dec 21 2018 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 6.84 | 1 | 7 | 1 | |
Dec 21 2018 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Option Exercise | J | 6.91 | 1 | 7 | 1 |
Page: 1